A nanoassembly includes a core protected by a biocompatible shell. The nanoassembly includes a plurality of block copolymers including drug-binding linkers and block copolymer cross-linkers. A first active agent is covalently conjugated to the plurality of block copolymers and a second active agent is physically entrapped in the core.